Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-BLISOVI FE vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Acne vulgaris (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Hepatic via CYP3A4 (ethinyl estradiol) and primarily conjugation (norethindrone); first-pass metabolism.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Ethinyl estradiol: 95-98% bound to albumin and sex hormone-binding globulin (SHBG)
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Ethinyl estradiol: 2-5 L/kg; indicates extensive tissue distribution
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: ethinyl estradiol approximately 40-50% (first-pass metabolism)
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
No dose adjustment required in renal impairment. Use with caution if severe renal impairment or nephrotic syndrome due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh class C). Not recommended in moderate impairment (Child-Pugh B) without specialist advice. No data for mild (Child-Pugh A); use caution.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not indicated in pediatric patients before menarche. For postmenarchal females, same adult dose may be used; weight-based dosing not established.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Not indicated in postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thrombotic events and comorbidities.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events from COC use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Thrombotic disorders (DVT, PE, stroke, MI),Carcinoma (breast, cervical, liver),Hepatic disease (jaundice, cholestasis),Hypertension,Carbohydrate/lipid effects,Headache/migraine,Bleeding irregularities,Drug interactions (CYP3A4 inducers/inhibitors),Depression,Gallbladder disease,Hereditary angioedema
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Venous or arterial thrombotic/thromboembolic events (current or history),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Uncontrolled hypertension,Major surgery with prolonged immobilization,Diabetes with vascular involvement,Headache with focal neurological symptoms or migraine with aura (age ≥35),Current or history of breast cancer or other estrogen-sensitive neoplasia,Hepatic adenomas or malignant liver tumors,Acute or chronic liver disease with abnormal function,Undiagnosed abnormal uterine bleeding,Known or suspected pregnancy,Cigarette smoking in women >35 years,Hypersensitivity to any component
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Grapefruit juice may increase estrogen levels and risk of adverse effects; avoid large quantities. Iron absorption is enhanced by vitamin C (e.g., orange juice) and inhibited by tannins (tea, coffee), calcium (dairy), and phytates (whole grains); separate iron intake from these foods by at least 2 hours. Take with food to reduce GI upset.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-trimester exposure, and potential feminization of male fetuses from progestin exposure. Post-conception use is not indicated; if exposure occurs, evaluate for pregnancy.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Small amounts of progestins and estrogens are excreted in breast milk; M/P ratio not established for this specific formulation. Use in breastfeeding women is generally not recommended due to potential effects on milk production and composition, and possible long-term effects on the infant. Alternative contraception methods are advised until weaning.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Contraindicated in pregnancy. If pregnancy occurs, discontinue immediately. No dose adjustment is applicable as the drug should not be used in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) are irrelevant due to contraindication.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
LO-BLISOVI FE (norethindrone acetate/ethinyl estradiol/ferrous fumarate) is a combined oral contraceptive with iron supplementation. The iron component (75 mg ferrous fumarate) compensates for menstrual blood loss. Administer at the same time daily to maintain stable hormone levels. Missed doses increase risk of breakthrough bleeding and contraceptive failure. Consider non-oral contraceptives in patients with malabsorption or vomiting.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one tablet daily at the same time with food to reduce nausea.,Missed doses: if one dose is missed >12 hours, take it immediately and continue; if two doses are missed, take two tablets and use backup contraception for 7 days.,Iron tablets may cause dark stools; this is harmless.,Report severe headache, chest pain, leg swelling, or vision changes immediately.,Do not smoke while taking this medication; smoking increases risk of blood clots.,Store in original blister pack; do not remove desiccant.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-BLISOVI FE vs DESOGEN, answered by our medical review team.
LO-BLISOVI FE is a Combination Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-BLISOVI FE and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-BLISOVI FE is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-BLISOVI FE and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-BLISOVI FE is classified as Category C. Pregnancy category X. Combination hormonal contraceptives are contraindicated in pregnancy due to known risks to the fetus, including cardiovascular and limb defects from first-tri. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.